Journal
ATHEROSCLEROSIS
Volume 228, Issue 1, Pages 12-17Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2013.01.024
Keywords
Metalloproteinase; Inflammation; Obesity; Macrophages; Insulin resistance; Steatosis
Funding
- Juvenile Diabetes Research Foundation Regular Research [1-2007-665]
- Telethon [GGP08065]
- Fondazione Roma [FP7-Health-241913]
- FP-7 EURHYTHDIA
- PRIN [2009FATXW3_002]
Ask authors/readers for more resources
The TNF-alpha Converting Enzyme (TACE), also called ADAM17 (A Disintegrin and A Metalloproteinase 17) is a type I transmembrane metalloproteinase involved in the shedding of the extracellular domain of several transmembrane proteins such as cytokines, growth factors, receptors and adhesion molecules. Some of these proteolytic events are part of cleavage cascades known as Regulated Intramembrane Proteolysis and lead to intracellular signaling. Evidence is provided that ADAM17 plays a role in atherosclerosis, in adipose tissue metabolism, insulin resistance and diabetes. The multitude of substrates cleaved by ADAM17 makes this enzyme an attractive candidate to study its role in inflammatory disorders. This review is focused on effects of ADAM17 in major metabolic tissues. (c) 2013 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available